Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 5, 2011, Pages 414-420

  Almasi, Martina ^a   Sevcikova, Sabina ^a   Slaby, Ondrej ^a   Kaisarova, Petra ^a   Maisnar, Vladimir ^b   Penka, Miroslav ^c   Pika, Tomas ^d   Pour, Ludek ^a,c   Radocha, Jakub ^b   Scudla, Vlastimil ^d   Svachova, Hana ^a   Hajek, Roman ^a,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Allelic discrimination; Classification tree; Genotype; Real time polymerase chain reaction; Single nucleotide polymorphisms

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM; GENE FREQUENCY; GENETICS; MIDDLE AGED; PROGNOSIS; RISK;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; THALIDOMIDE; VENOUS THROMBOEMBOLISM;

EID: 84856144389     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.024     Document Type: Article

References (28)

1. Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. J Surg Oncol 2007; 96:265-72. (Pubitemid 350194627)
2. Connolly GC, Horana AA. Risk stratification for cancer-associated venous throm-boembolism. Best Pract Res Clin Haematol 2009; 22:35-47.
3. Swystun LL, Shin LY, Beaudin S, et al. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood mono-cytes. J Tromb Haemost 2009; 7:619-26.
4. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-asso-ciated thromboembolism among patients with cancer. JAMA 2006; 296:2558-60. (Pubitemid 44903859)
5. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71. (Pubitemid 34864267)
6. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-23. (Pubitemid 35266292)
7. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002; 100:2272-3. (Pubitemid 35001274)
8. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexa-methasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89:826-31. (Pubitemid 38981342)
9. Elice F, Rodeghiero F, Falanga A, et al. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009; 22:115-28.
10. Rak J, Milsom C, Yu J. Tissue factor in cancer. Curr Opin Hematol 2008; 15:522-8.
11. Lopez-Pedrera C, Barbarroja N, Dorado G, et al. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 2006; 20:1331-40. (Pubitemid 44084043)
12. Minnema MC, Fijnheer R, De Groot PG, et al. Extremely high levels of von Willlebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Tromb Haemost 2003; 1:445-9.
13. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol He-matol 2007; 62:126-36. (Pubitemid 46575277)
14. Auwerda JJ, Sonneveld P, de Maat MP, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92:279-80. (Pubitemid 46852441)
15. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73: 145-50. (Pubitemid 33758853)
16. Musallam KM, Dahdaleh FS, Shamseddine AI, et al. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immuno-modulatory therapy. Thromb Res 2009; 123:679-86.
17. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyp-ing. Blood 2008; 112:4924-34.
18. Lakhorst HM, Breitkreuz B, van der Holt E. First interim analysis of the joint HOVON-50/GMMG-HD3 randomized study effect of thalidomide combined with adriamycin, dexamethasone and HD melphalan in patients with multiple myeloma. Haematologica 2005; 90 (suppl 1):56.
19. Lenalidomide [package insert]. Silver Spring MD: US Food and Drug Administration; 2006. Available at: http://www.fda.gov/cder/foi/label/2006/ 021880s001.pdf. Accessed: November 1, 2008.
20. European Medicines Agency. Questions and answers on the positive opinion for Thalidomide Pharmion. 2008. Available at: http://www.emea.europa.eu/pdfs/hu- man/opinion/Q&AThalidomide54352407en.pdf. Accessed: January 2, 2008.
21. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414-23. (Pubitemid 351255436)
22. Klein U, Kosely F, Hillengass J, et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88:67-71.
23. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning. 2009. Available at: http://www-stat.stanford.edu/~tibs/ElemStatLearn/. Accessed: February 1, 2009.
24. Ye Y, Yang H, Grossman HB, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008; 112:2467-74.
25. Choi YY, Kang HK, Choi JE, et al. Comprehensive assessment of P21 polymorphisms and lung cancer risk. J Hum Genet 2008; 53:87-95.
26. Driver KE, Song H, Lesueur F, et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcino-genesis 2008; 29:333-41. (Pubitemid 351359672)
27. Chang BL, Zheng SL, Isaacs SD, et al. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004; 64: 1997-9. (Pubitemid 38339445)
28. Goode EL, Fridley BL, Vierkant RA, et al. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:935-44.